Orion Biotechnology Polska

Orion Biotechnology is a biopharmaceutical company specializing in the development of novel biologics that target G Protein-Coupled Receptors (GPCRs). The company leverages its proprietary Precision Receptor Optimization (PRO-platform) to create high-potency peptide and protein therapeutics for previously undruggable targets. Its lead program, OB-002, is a potent CCR5 antagonist designed for HIV prevention and the treatment of solid tumors. Orion Biotechnology Polska serves as the primary research and development hub for the organization, supporting a pipeline focused on oncology, infectious diseases, and neuroinflammation. The company's technology allows for the rapid discovery of candidates with significantly higher potency than traditional small molecules or antibodies.